Stay updated on Blinatumomab & Pembrolizumab in B-ALL Clinical Trial

Sign up to get notified when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.3.2 was added and Revision: v3.2.0 was removed from the page. This is a version update and does not modify the study details or other user-facing content.
    Difference
    0.1%
    Check dated 2025-11-25T13:43:47.000Z thumbnail image
  3. Check
    22 days ago
    Change Detected
    Summary
    Administrative date-stamp updates have been added (Results First Posted [Estimated], Certification/Extension First Posted [Estimated], Last Update Posted [Estimated]), and a funding-status notice has been removed. These changes do not affect the study details, eligibility, or results.
    Difference
    0.7%
    Check dated 2025-11-18T07:23:42.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Added final results for NCT03160079, including ORR (CR+CRh), MRD negativity, 2-year relapse-free survival, and 2-year overall survival, and updated the study status to Completed with results posted. Included investigator and location details and referenced study documents.
    Difference
    2%
    Check dated 2025-11-11T03:23:41.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page appears unchanged between the two screenshots; no notable updates to study details or eligibility criteria are evident.
    Difference
    0.4%
    Check dated 2025-10-27T21:08:16.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    New operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.
    Difference
    3%
    Check dated 2025-10-06T08:25:21.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Expanded and reclassified content around lymphoma and viral infections with a new v3.1.0 revision; older leukemia-related terms and the previous v3.0.2 revision are removed.
    Difference
    2%
    Check dated 2025-09-29T05:09:15.000Z thumbnail image

Stay in the know with updates to Blinatumomab & Pembrolizumab in B-ALL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.